NCT04903054: Selective CD28 Blockade in Renal Transplant Recipients |
|
|
| Withdrawn | 2 | 54 | US | Lulizumab, BMS-931699, anti-CD28 domain antibody (anti-CD28 dAb), Tacrolimus, Prograf®, Thymoglobulin®, antithymocyte globulin, Methylprednisolone, corticosteroid, Mycophenolate Mofetil, MMF, CellCept®, Prednisone | National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb, PPD | Kidney Transplantation, Renal Transplant Recipients | 09/22 | 09/22 | | |
NCT04066114: Treg Modulation With CD28 and IL-6 Receptor Antagonists |
|
|
| Completed | 1/2 | 10 | US | lulizumab pegol, BMS-931699, antithymocyte globulin (rabbit), ATG (rabbit), Thymoglobulin®, methylprednisolone, Solu-Medrol ®, tocilizumab, Actemra®, Prednisone, prednisone tablets, Rayos®, everolimus, Zortress®, belatacept, Nulojix®, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, Myfortic® | National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb, Clinical Trials in Organ Transplantation | Living-Donor Kidney Transplant, Kidney Transplant Recipients | 09/23 | 09/23 | | |